[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
Service de médecine interne, hôpital Robert-Bisson, 14100 Lisieux, France. l.geffray@ch-lisieux.fr
L
L
Geffray
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000379:methods; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D005602:France; D006801:Humans; D007388:Internal Medicine; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012955:Societies, Medical; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D008558:Melphalan